Minerva Neurosciences, Inc (NERV) CFO Sells $33,749.91 in Stock
Minerva Neurosciences, Inc (NASDAQ:NERV) CFO Geoff Race sold 5,829 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total value of $33,749.91. Following the completion of the sale, the chief financial officer now directly owns 197,698 shares in the company, valued at $1,144,671.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Minerva Neurosciences, Inc (NASDAQ:NERV) traded up $0.20 during midday trading on Monday, reaching $5.95. The company’s stock had a trading volume of 600,300 shares, compared to its average volume of 219,098. Minerva Neurosciences, Inc has a 1 year low of $4.80 and a 1 year high of $13.95.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter. During the same period in the previous year, the business earned ($0.24) earnings per share. equities analysts anticipate that Minerva Neurosciences, Inc will post -1.28 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of NERV. Nationwide Fund Advisors grew its stake in shares of Minerva Neurosciences by 14.2% in the second quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,616 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Minerva Neurosciences by 54.6% in the second quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 5,579 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Minerva Neurosciences in the second quarter worth $145,000. State of Wisconsin Investment Board bought a new position in shares of Minerva Neurosciences in the second quarter worth $159,000. Finally, Alpine Woods Capital Investors LLC grew its stake in shares of Minerva Neurosciences by 100.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 20,000 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 10,000 shares in the last quarter. 73.76% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have weighed in on the company. Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Citigroup assumed coverage on Minerva Neurosciences in a research report on Friday, September 1st. They issued a “buy” rating and a $11.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Minerva Neurosciences currently has a consensus rating of “Hold” and a consensus target price of $13.94.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://theolympiareport.com/2017/12/18/minerva-neurosciences-inc-nerv-cfo-sells-33749-91-in-stock.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.